Difference between revisions of "Imipramine-moclobemide"

From Psychiatrienet
Jump to: navigation, search
 
Line 3: Line 3:
 
| to = moclobemide  
 
| to = moclobemide  
 
| stop =  
 
| stop =  
{{stopImipramine}}  
+
{{Generaldecrease25p3d}}
 +
{{7dWashout}}
 
| start =  
 
| start =  
* '''Day 8-14:''' a wash-out period of one week is necessary.
+
{{MAOIncrease25p}}
* '''Day 15:''' start administration of moclobemide in a dosage of 150 mg/day.
 
* '''Day 18:''' increase dosage of moclobemide to 300 mg/day.
 
 
| caveat =
 
| caveat =
 
{{caveSS}}
 
{{caveSS}}
 
}}
 
}}

Latest revision as of 13:44, 16 June 2016

Imipramine
Type Antidepressant
Group TCA
links
Medscape Imipramine
PubChem 3696
PubMed Imipramine
Kompas (Dutch) Imipramine
Wikipedia Imipramine
Moclobemide
Type Antidepressant
Group MAO-I
links
Medscape Moclobemide
PubChem 4235
PubMed Moclobemide
Kompas (Dutch) Moclobemide
Wikipedia Moclobemide

Switch medication from imipramine to moclobemide.[1] [2]

Nietinrijdenbord.png Stop imipramine
  • Decrease with about 25% of original dose every 3 days
  • Stop and wait 7 days for washout
Eenrichtingbord.png Start moclobemide
  • Start at the first day after the washout period with about 25% of target dose.
Letopbord.png Cave


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.